Related Experiment Video
Updated: Jun 21, 2026
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
Published on: November 13, 2010
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial
Eleanor J Cole1, Angela L Phillips1, Brandon S Bentzley1
1Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, Calif. (all authors except King and Sudheimer); U.S. Department of Veterans Affairs, Palo Alto, Calif. (Phillips, Azeez, Coetzee); Department of Psychology, Palo Alto University, Palo Alto, Calif. (Stimpson, Cherian, Felber, Brown, Choi); Centre for Neuroimaging and Cognitive Genomics, National University of Ireland, Galway (King); Department of Anatomy, School of Medicine, Southern Illinois University, Carbondale (Sudheimer).
Stanford neuromodulation therapy (SNT) significantly improved treatment-resistant depression symptoms compared to sham treatment. This accelerated intermittent theta-burst stimulation (iTBS) protocol shows promise for faster, more effective depression treatment.
Area of Science:
- Neuroscience
- Psychiatry
- Medical Imaging
Background:
- Treatment-resistant depression (TRD) affects half of all depression patients, representing a significant global health challenge.
- Current intermittent theta-burst stimulation (iTBS) for TRD has suboptimal efficacy and requires a lengthy 6-week duration.
- Stanford neuromodulation therapy (SNT) is an accelerated iTBS protocol designed to overcome these limitations.
Purpose of the Study:
- To evaluate the efficacy of SNT compared to sham stimulation in patients with TRD.
- To assess the impact of a neuroscience-informed, accelerated iTBS protocol on depressive symptoms.
Main Methods:
- A double-blind, sham-controlled trial involving participants with moderate to severe TRD.
- Individualized targeting of the left dorsolateral prefrontal cortex using resting-state functional MRI.
- Primary outcome measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) at 4 weeks post-treatment.
Main Results:
- The active SNT group showed a 52.5% mean reduction in MADRS scores 4 weeks after treatment.
- The sham SNT group exhibited only an 11.1% mean reduction in MADRS scores.
- A statistically significant difference in symptom reduction was observed between active and sham SNT groups.
Conclusions:
- High-dose, functional-connectivity-guided SNT is more effective than sham stimulation for TRD.
- SNT demonstrates potential as an accelerated and effective treatment for treatment-resistant depression.
- Further research is required to establish SNT's long-term durability and comparative effectiveness.
